NAV

Tinengotinib

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Tinengotinib
DrugBank Accession Number
DB17384
Background

Not Available

Type
Small Molecule
Groups
Investigational
Structure
3D
Similar Structures
Weight
Average: 394.86
Monoisotopic: 394.130887
Chemical Formula
C20H19ClN6O
Synonyms
  • 4-(5-(2-Chlorophenyl)-3-Methyl-2,10-Dihydropyrazolo[4,3-B] Pyrido[4,3-E][1,4]Diazepin-8-Yl) Morpholine
  • 5-(2-chlorophenyl)-3-methyl-8-(morpholin-4-yl)-1,10-dihydropyrazolo[4,3-b]pyrido[4,3-e][1,4]diazepine
  • Pyrazolo(4,3-b)pyrido(4,3-e)(1,4)diazepine, 5-(2-chlorophenyl)-1,2-dihydro-3-methyl-8-(4-morpholinyl)-
External IDs
  • TT-00420

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
WZ9TJ0L9Y8
CAS number
2230490-29-4
InChI Key
DQFCVOOFMXEPOC-UHFFFAOYSA-N
InChI
InChI=1S/C20H19ClN6O/c1-12-18-20(26-25-12)23-16-10-17(27-6-8-28-9-7-27)22-11-14(16)19(24-18)13-4-2-3-5-15(13)21/h2-5,10-11H,6-9H2,1H3,(H2,23,25,26)
IUPAC Name
9-(2-chlorophenyl)-6-methyl-13-(morpholin-4-yl)-2,4,5,8,12-pentaazatricyclo[8.4.0.0^{3,7}]tetradeca-1(10),3,6,8,11,13-hexaene
SMILES
CC1=C2N=C(C3=CC=CC=C3Cl)C3=C(NC2=NN1)C=C(N=C3)N1CCOCC1

References

General References
Not Available
ChemSpider
115008005
PDBe Ligand
KX0
PDB Entries
8h75

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3Not Yet RecruitingTreatmentCholangiocarcinoma1
2Active Not RecruitingTreatmentCholangiocarcinoma / FGFR1 Alteration / FGFR2 Fusion / FGFR2 Gene Mutation / FGFR3 Alteration1
2Not Yet RecruitingTreatmentMetastatic Cholangiocarcinoma1
1Active Not RecruitingTreatmentAdvanced Solid Tumors / Triple-Negative Breast Cancer1
1CompletedOtherHealthy Subjects (HS)1
1, 2Active Not RecruitingTreatmentAdvanced Solid Tumors / Bladder Cancer / Cholangiocarcinoma / Gallbladder Cancer / Gastric Cancer / Human Epidermal Growth Factor 2 Negative Carcinoma of Breast / Prostate Cancer / Sarcomas / Small Cell Lung Cancer (SCLC) / Thyroid Cancer / Triple-Negative Breast Cancer1
1, 2RecruitingTreatmentAdvanced Solid Tumors / Bile Duct Cancer / Bladder Cancer / Cholangiocarcinoma / Gallbladder Cancer / Gastric Cancer / Human Epidermal Growth Factor 2 Negative Carcinoma of Breast / Prostate Cancer / Small Cell Lung Cancer (SCLC) / Thyroid Cancer / Triple-Negative Breast Cancer1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0474 mg/mLALOGPS
logP3.73ALOGPS
logP4.03Chemaxon
logS-3.9ALOGPS
pKa (Strongest Acidic)11.86Chemaxon
pKa (Strongest Basic)6.57Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count6Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area78.43 Å2Chemaxon
Rotatable Bond Count2Chemaxon
Refractivity113.42 m3·mol-1Chemaxon
Polarizability41.33 Å3Chemaxon
Number of Rings5Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created at December 22, 2022 18:17 / Updated at December 23, 2022 00:49